Trial Profile
Study of ranibizumab versus aflibercept for treatment of neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Aug 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 14 Aug 2018 New trial record